Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q2 Revenues Rise 16 Percent as It Searches for New CEO

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Response Genetics today announced its second-quarter revenues increased 16 percent year over year to $6.7 million from $5.6 million a year ago.

The spike was due mainly to a 74 percent increase in pharmaceutical service revenues to $3.7 million from $2.1 million a year ago, the Los Angeles-based company said, while Response Dx genetic test revenues were down 15 percent to $3 million from $3.5 million, due to a one-time revenue adjustment of $1.5 million a year ago for the adoption of the accrual basis of accounting.

The firm's net loss for the quarter was skimmed to $87,344, or $.00 per share, from a loss of $425,038, or $.02 per share, a year ago.

Its R&D expenses contracted 75 percent year over year to $221,546 from $388,046 a year ago, but SG&A costs jumped 81 percent to $3.8 million from $2.1 million a year ago.

Response Genetics exited the quarter with $4.1 million in cash and cash equivalents.

The company also disclosed today that Kathleen Danenberg stepped down as CEO on July 22 and was appointed by the company's board as founder and executive scientific and technology officer. Denise McNairn, vice president, general counsel, and secretary, is serving as interim CEO as the company searches for a permanent replacement.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.